Application and Development of Artificial Intelligence in A Pathological Study of Urinary System Tumors / 肿瘤防治研究

Global Cancer Statistics for 2020 show that urinary system tumors account for approximately 13% of the total number of cancers. At present, the diagnostic methods of urinary system tumors are imaging, endoscopy, and pathological examination. As the gold standard of tumor diagnosis, pathological examination has problems such as lack of pathologists and long operation time. Artificial intelligence (AI), with a strong ability for pathology image recognition and feature analysis, can be used as an auxiliary diagnosis. It has realized automatic diagnosis, typing, staging, grading, and prognosis prediction in several urinary system tumors. However, AI still has many shortcomings, which limit its clinical application. This article will review the progress of AI and its application in the pathological study of urinary system tumors.

Progress of Different Programmed Cell Death Pathways in Kidney Cancer / 肿瘤防治研究

Programmed cell death (PCD) is a genetically determined, active and orderly cell death in the organism, and it affects the evolution of the organism, maintenance of its homeostasis, and development of several tissues and organs. The abnormal regulation of this process is closely related to various human diseases, including cancer. The identified pathways of PCD include apoptosis, autophagy, necroptosis, pyroptosis, and ferroptosis, which can be activated when cells are stimulated by various internal and external environmental factors. These pathways can induce cell death or maintain cell survival in kidney cancer cells under the regulation of various signaling molecules, thus affecting tumor progression or therapeutic efficacy. In this paper, the role of these PCD pathways in the development of kidney cancer was reviewed in light of recent research advances to provide new directions for the in-depth study of the pathogenesis of kidney cancer and the development of targeted antitumor drugs.

Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2 / 医学前沿

Aldolase B (ALDOB), a glycolytic enzyme, is uniformly depleted in clear cell renal cell carcinoma (ccRCC) tissues. We previously showed that ALDOB inhibited proliferation through a mechanism independent of its enzymatic activity in ccRCC, but the mechanism was not unequivocally identified. We showed that the corepressor C-terminal-binding protein 2 (CtBP2) is a novel ALDOB-interacting protein in ccRCC. The CtBP2-to-ALDOB expression ratio in clinical samples was correlated with the expression of CtBP2 target genes and was associated with shorter survival. ALDOB inhibited CtBP2-mediated repression of multiple cell cycle inhibitor, proapoptotic, and epithelial marker genes. Furthermore, ALDOB overexpression decreased the proliferation and migration of ccRCC cells in an ALDOB-CtBP2 interaction-dependent manner. Mechanistically, our findings showed that ALDOB recruited acireductone dioxygenase 1, which catalyzes the synthesis of an endogenous inhibitor of CtBP2, 4-methylthio 2-oxobutyric acid. ALDOB functions as a scaffold to bring acireductone dioxygenase and CtBP2 in close proximity to potentiate acireductone dioxygenase-mediated inhibition of CtBP2, and this scaffolding effect was independent of ALDOB enzymatic activity. Moreover, increased ALDOB expression inhibited tumor growth in a xenograft model and decreased lung metastasis in vivo. Our findings reveal that ALDOB is a negative regulator of CtBP2 and inhibits tumor growth and metastasis in ccRCC.

Survival analysis of kidney cancer in Qidong City from 1972 to 2016 / 预防医学

Objective@#To investigate the survival rate and changing trends of kidney cancer patients in Qidong City from 1972 to 2016, so as to provide insights into kidney cancer control.@*Methods@#Data pertaining to the incidence of kidney cancer in Qidong City from 1972 to 2016 were captured from the Qidong Municipal Cancer Registration System, and the final follow-up period was December 31, 2021. The observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer were calculated to analyze the survival of kidney cancer, and the trends in survival were analyzed among kidney cancer patients from 1972 to 2016 using annual percent change (APC).@*Results@# A total of 554 kidney cancer patients were reported in Qidong City from 1972 to 2016. The 1-, 3- and 5-year observed survival rates, relative survival rates and standardized relative survival rates were 62.27%, 50.54% and 44.04%; 64.31%, 55.71% and 51.93%; and 61.71%, 51.90%, and 51.68%, respectively. The 5-year observed survival rate, relative survival rate and standardized relative survival rate of kidney cancer appeared a tendency towards a rise in Qidong City from 1972 to 2016, with APC of 2.83% (t=4.303, P=0.004), 2.82% (t=3.978, P=0.005) and 3.96% (t=5.898, P=0.001), and the 5-year relative survival rate of kidney cancer was comparable between men and women (53.05% vs. 50.40%; χ2=4.872, P=0.676). There was an age-specific 5-year relative survival rate of kidney cancer (χ2=35.144, P<0.001), with the greatest among patients at ages of 35 to 44 years (64.49%) and the lowest at ages of 75 years and older (30.11%).@*Conclusion@#The 5-year survival rate of kidney cancer cases appeared a tendency towards a rise in Qidong City from 1972 to 2016. Further specific interventions, depending on age, are needed for management of kidney cancer.

Etude rétrospective des cancers rénaux dans le service d'oncologie médicale CHU Annaba (2008-2016) / Retrospective study of kidney cancer in the department of medical oncology of Annaba university hospital (2008-2016)

Objectif. Notre étude avait pour objectif de dégager le profil épidémiologique, clinique, histopathologique, thérapeutique et évolutif des cancers rénaux dans le centre anti cancer Annaba Algérie. Patients et méthodes. Etude rétrospective incluant 50 cas de cancers rénaux traités au sein des services d'oncologie médicale CHU Annaba entre janvier 2008 et octobre 2016. Résultats. Il s'agissait de 30 hommes et de 20 femmes. L'âge moyen de découverte était de 51 ans (extrêmes : 23-79 ans). Le facteur de risque le plus fréquemment observé était le tabagisme (58 %) suivi par l'hypertension artérielle (40 %). La douleur lombaire était le signe révélateur le plus fréquemment noté chez 48 % des patients. Le diagnostic a été basé sur la tomodensitométrie chez 100 % des patients. 54 % des tumeurs étaient localisées dans le rein droit. 42 % des patients étaient de groupe pronostique intermédiaire. La néphrectomie était pratiquée chez 90 % des patients. Le type histologique prédominant était le carcinome rénal à cellule claire (70 %), le grade de Fuhrman prédominant (grade 2 et 3) (36%). 86 % des patients étaient métastatique. 37.2 % des patients avaient 2 sites métastatiques. Parmi les 50 malades, 43 avaient reçu un traitement systémique versus 7 une surveillance. En 1ère ligne un inhibiteur de tyrosine kinase a était administré chez 41 malades (sunitinib (35pts) /sorafénib (6pts)), chimiothérapie associée à un anti angiogenèse chez deux malades. Sunitinib schéma (4/2) a était utilisé chez 19 pts versus (2/1) chez 14 pts, une réduction de dose a été pratiquée chez 18 pts. Les effets secondaires les plus rencontrés ont était l'asthénie (14 tous grades/09 grade 3et 4), syndrome main/pied (08 tous grades/05 grades 3 et 4), mucite (11 pts), neutropénie (8 pts), hypertension artérielle (5 pts), hypothyroïdie (5 pts). Neuf malades avaient reçu une 2ème ligne de traitement, un malade une 3ème ligne thérapeutique. L'évolution des malades était : 14 % (surveillance) ,4 % (RC) ,14 % (RP), (MP) ,60 % décédés. La médiane de survie globale était de 38,5 mois avec des extrêmes de 3 et de 74 mois. Conclusion. Le cancer rénal dans notre population était rencontré chez le sujet de la cinquième décennie avec prédominance masculine, la symptomatologie clinique était polymorphe dominée par des signes urologiques, la majorité des patients ont été métastatiques. Presque la totalité avait bénéficié d'une néphrectomie. Les inhibiteurs de tyrosine kinase ont été le traitement de choix de première ligne chez la majorité des malades avec une amélioration significative de la survie globale mais au prix d'une toxicité importante.

Tumor renal con extensión al atrio derecho a través de la vena cava inferior: reporte de caso / Renal tumor with extension to the right atrium through the inferior vena cava: case report

Resumen El presente articulo describe un caso clínico de una paciente con un ''trombo tumoral''. Estos son tumores que se extienden desde el órgano afectado hasta el atrio derecho, por la vena cava inferior. Hasta el 10 % de los tumores descritos pueden alcanzar la vena cava inferior y el 1 % de estos llegan a atrio derecho. El carcinoma de células renales es el más frecuente en producir este cuadro. El objetivo del articulo es mostrar que es fundamental realizar un adecuado diagnóstico diferencial, ya que existen diferentes procesos tumorales que pueden causar un ''trombo tumoral'' y diferentes causas de masas en el atrio derecho. La clínica de los pacientes con este cuadro será por obstrucción de la vena cava. El diagnóstico se realiza con estudios de imágenes, ultrasonido (US), ecocardiograma, tomografía axial computarizada (TAC) y resonancia magnética. El manejo debe de ser quirúrgico, sin embargo, presenta pronóstico desfavorable, en algunos casos se puede resecar el tumor primario y extraer la masa que ha invadido la vena cava inferior.

Abstract: This article describes a clinical case of a patient with a 'tumoral thrombus''. These are tumors that extend from the affected organ to the right atrium, through the inferior vena cava. Up to 10% of the tumors described can reach the inferior vena cava and 1% of these reach the right atrium. Renal cell carcinoma is the most common to produce this condition. The objective of the article is to show that it is essential to carry out an adequate differential diagnosis since there are different tumor processes that can cause a ''tumoral thrombus'' and different causes of masses in the right atrium. The symptoms of patients with this condition will be caused by the obstruction of the vena cava. The diagnosis is made with imaging studies, ultrasound (US), echocardiography, computerized axial tomography (CT) and magnetic resonance imaging. The management must be surgical, however it has an unfavorable prognosis, in some cases the primary tumor can be resected and the mass that has invaded the inferior vena cava removed.

Characteristics and Surgical Outcomes in Very Elderly Patients (≥75 years) with Renal Cell Carcinoma: Data from the Latin American Renal Cancer Group

Background: The incidence of renal cell carcinoma (RCC) is increasing globally due to an aging population and widespread use of imaging studies. Objective: The aim of this study was to describe the characteristics and perioperative outcomes of RCC surgery in very elderly patients (VEP), ≥75 years of age. Methods: This is a retrospective comparative study of 3656 patients who underwent the treatment for RCC from 1990 to 2015 in 28 centers from eight Latin American countries. We compared baseline characteristics as well as clinical and perioperative outcomes according to age groups (<75 vs.≥ 75 years). Surgical complications were classified with the Clavien-Dindo score. We performed logistic regression analysis to identify factors associated with perioperative complications. Results: There were 410 VEP patients (11.2%). On bivariate analysis, VEP had a lower body mass index (p < 0.01) and higher ASA score (ASA >2 in 26.3% vs. 12.4%, p < 0.01). There was no difference in performance status and clinical stage between the study groups. There were no differences in surgical margins, estimated blood loss (EBL), complication, and mortality rates (1.3% vs. 0.4%, p = 0.17). On multivariate regression analysis, age ≥75 years (odds ratio [OR] 2.33, p < 0.01), EBL ≥ 500 cc (OR 3.34, p < 0.01), and > pT2 stage (OR 1.63, p = 0.04) were independently associated with perioperative complications. Conclusions: Surgical resection of RCC was safe and successful in VEP. Age ≥75 years was independently associated with 30-day perioperative complications. However, the vast majority were low-grade complications. Age alone should not guide decision-making in these patients, and treatment must be tailored according to performance status and severity of comorbidities. (REV INVEST CLIN. 2020;72(5):308-15)

Effect of crocin on PKHD1 and KLLN genes expression in kidney tissue of male rats treated with cadmium / Efecto de la crocina sobre la expresión de los genes PKHD1 y KLLN en tejido renal de ratas macho tratadas con cadmio

According to data from studies, antioxidant herbal compounds are, likely to have a useful role in reducing the harmful effects of environmental pollutants and toxic chemicals that most people are exposed to. Cadmium is one of the toxic elements that accumulate in many organs, especially in kidneys. The aim of this study was to investigate the effect of crocin on the expression of PKHD1 and KLLN genes in cadmium-treated rats.In this experimental study, 40 adults male Wistar rats (200-250 g) were randomly divided into the following groups: control group received normal saline, cadmium group (15mg/kg), crocin group (20mg/kg) and cadmium group daily fed with crocin at a dose of 20 mg/kg.After eight weeks of treatment, rats were dissected, and kidney tissues were removed for evaluation of PKHD1 and KLLN gene expression by real time method. The data were analyzed using one-way ANOVA and significant difference between groups was P<0.05.Our results showed an increase in PKHD1 gene expression and a decrease in KLLN gene expression in kidney tissue in the cadmium group compared to the control group (P <0.001).Also, a significant decrease in PKHD1 gene expression (P <0.001) and an increase in KLLN gene expression P <0.05) were observed in the tissues of all cadmium-treated rats compared to cadmium.Crocin consumption can have a protective effect against the impaired expression of PKHD1 and KLLN cadmium-induced apoptotic pathway.

Diversos estudios sugieren que compuestos antioxidantes de hierbas tienen un papel útil en la reducción de los efectos nocivos de los contaminantes ambientales y los químicos tóxicos a los que está expuesta la mayoría de las personas. El cadmio es uno de los elementos tóxicos que se acumulan en muchos órganos, especialmente en los riñones. El objetivo de este estudio fue investigar el efecto de la crocina en la expresión de los genes PKHD1 y KLLN en ratas tratadas con cadmio.En este estudio experimental, 40 ratas Wistar macho adultas (200-250 g) se dividieron aleatoriamente en los siguientes grupos: el grupo de control recibió solución salina normal, el grupo de cadmio (15 mg / kg), el grupo de crocina (20 mg / kg) y el grupo de cadmio alimentado diariamente con crocina a una dosis de 20 mg / kg.Después de ocho semanas de tratamiento, se disecaron las ratas y se extrajeron los tejidos renales para evaluar la expresión de los genes PKHD1 y KLLN mediante un método en tiempo real. Los datos se analizaron mediante ANOVA de una vía y la diferencia significativa entre los grupos fue P <0,05.Nuestros resultados mostraron un aumento en la expresión del gen PKHD1 y una disminución en la expresión del gen KLLN en el tejido renal en el grupo de cadmio en comparación con el grupo de control (P <0,001).Además, se observó una disminución significativa en la expresión del gen PKHD1 (P <0,001) y un aumento en la expresión del gen KLLN P <0,05) en los tejidos de todas las ratas tratadas con cadmio en comparación con el cadmio.El consumo de crocina puede tener un efecto protector contra la expresión alterada de la vía apoptótica inducida por cadmio PKHD1 y KLLN.

Evaluating the clinical significance of SHMT2 and its co-expressed gene in human kidney cancer

BACKGROUND: Kidney cancer is one of the most common cancers in the world. It is necessary to clarify its underlying mechanism and find its prognostic biomarkers. Current studies showed that SHMT2 may be participated in several kinds of cancer. METHODS: Our studies investigated the expression of SHMT2 in kidney cancer by Oncomine, Human Protein Atlas database and ULCAN database. Meanwhile, we found its co-expression gene by cBioPortal online tool and validated their relationship in A498 and ACHN cells by cell transfection, western blot and qRT-PCR. Besides these, we also explored their prognostic values via the Kaplan-Meier plotter database in different types of kidney cancer patients. RESULTS: SHMT2 was found to be increased in 7 kidney cancer datasets, compared to normal renal tissues. For the cancer stages, ages and races, there existed significant difference in the expression of SHMT2 among different groups by mining of the UALCAN database. High SHMT2 expression is associated with poor overall survival in patients with kidney cancer. Among all co-expressed genes, NDUFA4L2 and SHMT2 had a high co-expression efficient. SHMT2 overexpression led to the increased expression of NDUFA4L2 at both mRNA and protein levels. Like SHMT2, overexpressed NDUFA4L2 also was associated with worse overall survival in patients with kidney cancer. CONCLUSION: Based on above results, overexpressed SHMT2 and its co-expressed gene NDUFA4L2 were all correlated with the prognosis in kidney cancer. The present study might be benefit for better understanding the clinical significance of SHMT2 and provided a potential therapeutic target for kidney cancer in future.

Enhancing immune effects of a DNA vaccine against kidney cancer using CD40L as an adjuvant

The use of specific combinations of antigens and adjuvant represents a promising approach for increasing the immunogenicity of DNA vaccines. In the present study, we evaluated the immunity and antitumor effects of DNA vaccines with G250 as the target antigen in a mouse model of renal cell carcinoma. We constructed two recombinant plasmids, pVAX1-G250 and pVAX1-CD40L. The recombinant plasmids were injected into mice by intramuscular injection and electrical pulse stimulation. ELISA and ELISPOT experiments were performed to evaluate the corresponding humoral and cellular immune responses following immunization. To further investigate the antitumor potential of the DNA vaccines, we established a tumor-bearing mouse model expressing G250 target antigen. Our results showed that immunization with the combination of the two plasmids exerted the strongest anti-tumor effects. Therefore, our findings demonstrated the effectiveness of CD40L as an adjuvant for DNA vaccines and highlighted the promising use of these vaccines for the treatment of tumors.

Carbonic anhydrase IX immunohistochemistry has potential to predict renal cell carcinoma outcomes: A systematic review and meta-analyses

@#Introduction: Tissue biomarker carbonic anhydrase IX (CAIX) is purported to have prognostic value for renal cell carcinoma (RCC) but contradicting findings from previous studies have also been documented. This study aims to perform a systematic review and meta-analysis on the role of CAIX in RCC disease progression. Materials and Methods: Following the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines, online searches of multiple databases were performed to retrieve articles from their inception until December 2017. Inclusion criteria included all English-based original articles of immunohistochemistry (IHC) studies investigating CAIX expression in human RCC tissue. Four articles were finally selected for meta-analysis with a total of 1964 patients. Standard meta-analysis methods were applied to evaluate the role of CAIX in RCC prognosis. The relative risk (RR) and its 95% confidence interval (CI) were recorded for the association between biomarker and prognosis, and data were analysed using MedCalc statistical software. Results: The meta-analysis showed that high CAIX expression was associated with low tumour stage (RR 0.90%, 95% CI 0.849-0.969, p= 0.004), low tumour grade (RR 0.835%, 95% CI 0.732-0.983, p= 0.028), absence of nodal involvement (RR 0.814%, 95% CI 0.712-0.931, p= 0.003) and better ECOS-PS index (RR 0.888%, 95% CI 0.818-0.969, p= 0.007). The high tissue CAIX expression in RCC is hence an indication of an early malignancy with a potential to predict favourable disease progression and outcome. Conclusion: The measurement of this marker may be beneficial to determine the course of the illness. It is hoped that CAIX can be developed as a specific tissue biomarker for RCC in the near future

One-year experience with 68Ga-PSMA PET/CT: applications and results in biochemical recurrence of prostate cancer / Experiência de um ano com PET/CT 68Ga-PSMA: aplicações e resultados na recidiva bioquímica do câncer prostático

Abstract Objective: To show the initial (first-year) experience with 68Ga-PSMA PET/CT at a clinic in Brazil. Materials and Methods: Over a one-year period, 96 examinations with 68Ga-PSMA PET/CT (85 related to prostate cancer and 11 related to kidney cancer) were performed in 90 patients. Results: In the prostate and kidney cancer patients alike, the main clinical indication for 68Ga-PSMA PET/CT was suspicion of recurrence during follow-up (in 65.8% and 63.0% of the cases, respectively). Among the prostate cancer patients, 38.5% of those with a prostate specific antigen (PSA) < 0.5 ng/mL tested positive for recurrence on 68Ga-PSMA PET/CT, compared with 71.0% of those with a PSA of 0.5-0.99, 85.7% of those with a PSA of 1.0-1.99, and 92.6% of those with a PSA > 1.99. Conclusion: Although 68Ga-PSMA PET/CT is a technique that has only recently been applied in clinical settings, despite its high cost, 68Ga-PSMA PET/CT shows great promise as a tool in the clinical management of patients with kidney and prostate cancer, especially in those with prostate cancer whose PSA levels are elevated even after treatment.

Resumo Objetivo: Mostrar a experiência inicial de exames de PET/CT com 68Ga-PSMA em uma clínica brasileira durante um ano. Materiais e Métodos: No período de um ano foram realizados 96 exames de PET/CT com 68Ga-PSMA, sendo 85 relacionados ao câncer de próstata e 11 relacionados ao câncer de rim, com o envolvimento de 90 pacientes. Resultados: Tanto no câncer prostático como no câncer renal, a principal indicação clínica foi suspeita de recidiva durante acompanhamento (65,8% e 63,0%, respectivamente). Nos casos de câncer de próstata, os exames foram positivos em 38,5% com o antígeno específico da próstata (PSA) menor que 0,5 ng/mL, em 71,0% com o PSA entre 0,5 e 0,99, em 85,7% com o PSA entre 1,0 e 1,99, e em 92,6% com o PSA maior que 1,99. Conclusão: O exame de PET/CT com 68Ga-PSMA, embora seja uma técnica de aplicação clínica recente e de custo elevado, é uma ferramenta bastante promissora no manuseio clínico de pacientes com câncer de rim e de próstata, principalmente para os casos de câncer de próstata já tratados e que apresentam elevação do PSA.

Nefrectomía radical derecha con resección de trombo tumoral en vena cava inferior nivel III / Right radical nephrectomy with inferior vena cava tumor thrombus level III

INTRODUCCIÓN: El CCR presenta una tendencia conocida a propagarse mediante la formación de trombo tumoral a la vena renal o vena cava inferior (4-10 por ciento ) El nivel que alcanza dicho tumor, está en directa relación con la sobrevida estimada a 5 años. MATERIALES Y MÉTODOS: Se presenta un caso de un paciente de sexo masculino de 58 años de edad, con antecedentes de Dm2 No IR y Tabaquismo crónico, el cual consulto por cuadro de 10 meses de evolución caracterizado por hematuria macroscópica. Dentro de la analítica sanguínea, destacaba paciente anémico, con hemoglobina de 8 g/dL y creatinemia de 1.1mg/mL. Se solicita URO-TAC, evidenciándose tumor renal derecho, de 18 cms en su eje largo, asociado a trombo en vena cava inferior, que se alojaba hasta el diafragma (Nivel III), no observándose metástasis a distancia o adenopatías de aspecto patológico. RESULTADOS: Se propone nefrectomía radical abierta por vía anterior, posteriormente se aísla y controla VCI, la cual se abre en su eje longitudinal. Se realiza trombectomia convencional con cierre primario, verificando hermeticidad del vaso. El tiempo operatorio total fue de 260 minutos, con un sangrado estimado de 1600ml. Se requirió transfusión de 3U de GR intraoperatorios sin incidentes reportados. El manejo post-operatorio inmediato fue en unidad de cuidados intensivos por 24 hrs, con un tiempo hospitalario total de 5 días. El paciente evoluciona favorablemente, sin complicaciones, destacando dentro de los exámenes de control, creatinina de 1.3 mg/dL. A la fecha, no hay evidencia de enfermedad residual clínica, o radiológica. CONCLUSIÓN: La nefrectomía radical convencional con trombo en vena cava inferior (nivel III) es el estándar de tratamiento para pacientes cáncer renal localmente avanzado en condiciones para afrontar la cirugía

INTRODUCTION: CCR presents a known trend to spread by means of a tumor thrombus in renal vein or inferior vena cava (4-10 pertcent ) The level reached by such tumor has a direct relation with the 5-year survival rate. MATERIALS AND METHODS: A 58-year old male patient presented with a history of Dm2 No IR and chronic tabaquism who enquired about 10-month symptoms, characterized by macroscopic hematuria. Amongst the blood analytics, an anemic patient stood out, whose hemoglobin level is 8 g/dL and 1.1mg/mL creatinemia. URO-TAC is requested which shows right kidney tumor, of 18 centimeters on its longer axis, associated to thrombus in the inferior vena cava, extended to the diaphragm (Level III), without presence of distant metastasis or adenopathies with pathological aspect. RESULTS: Anterior open radical nephrectomy is suggested, posteriorly isolated and VCI controlled, which is performed on its longitudinal axis. Conventional thrombectomy with primary closing and verification of vessel hermetism are performed. Operative time was 260 minutes. Estimated blood loss was 1600ml. 3U of GR intraoperative transfusion was required and no incidents were reported. Postoperative management took place in intensive care unit for 24 hours and the patient was discharged 5 days after surgery. The patient evolves favorably, without complications, presenting a 1.3 mg/dL creatinine level. To date, there is no evidence of clinical residual or radiological illness. CONCLUSION: Radical nephrectomy with inferior vena cava thrombus (level III) is the standard treatment for kidney cancer patient presenting local progression in a condition to withstand surgery.

¿Existen diferencias clínicas, patológicas y evolutivas del cáncer renal en relación con la edad? / Are there Clinical, Pathological and Evolutionary Differences in Renal Cancer Related to Age?

Objetivos: Evaluar las características clínicas, patológicas y evolutivas en diferentes grupos etarios con cáncer renal. Materiales y métodos: Se llevó a cabo un análisis retrospectivo, descriptivo y analítico de 269 pacientes con carcinoma de células renales. Los pacientes fueron divididos en tres grupos de acuerdo con la edad al momento del diagnóstico: <50 años, entre 50 y 65 años y >65 años. En cada grupo se evaluaron características clínicas (edad, sexo, presencia de manifestaciones clínicas), patológicas (diámetro tumoral, tipo histológico, estadío patológico [TNM 2009], grado histológico, presencia de necrosis coagulativa, invasión microvascular, presencia de elementos sarcomatoides, compromiso de la grasa periférica, compromiso vascular macroscópico de vena renal o cava inferior e invasión ganglionar) y presencia de metástasis a distancia al diagnóstico. El análisis univariado de las variables categóricas fue realizado por el método de chi cuadrado o test de Fischer según correspondiera; las variables continuas fueron calculadas según el test de Student. Los puntos principales del trabajo, la sobrevida libre de metástasis y la sobrevida cáncer-específica fueron evaluados mediante el método de Kaplan-Meier y las diferencias entre los grupos fueron evaluadas por el Log-Rank test. Resultados: De los 269 pacientes estudiados, 40 (14,88%) corresponden a <50 años, 136 (50,55%) corresponden a pacientes entre 50 y 65 años y 93 (34,57%) corresponden a pacientes >65 años de edad. No existieron diferencias significativas al evaluar variables clínicas. Los pacientes <50 años presentaron mayor número de nefrectomías parciales (p=0,04), menor grado histológico (p=0,05), necrosis coagulativa (p=0,002), infiltración de la grasa periférica (p=0,02) y compromiso ganglionar (p=0,05). La sobrevida libre de metástasis a 5 años en pacientes <50 años fue del 95%; en los grupos entre 50-65 años y >65 años fue del 70% y el 71%, respectivamente, con diferencias significativas (Log-Rank test=0,004). De la misma manera, al comparar la sobrevida cáncerespecífica a 5 años entre los grupos se pudo evidenciar que las diferencias también fueron significativas a favor de pacientes <50 años (<50 años del 98%, 50-65 años del 79% y >65 años del 83%; Log-Rank test=0,02). Conclusiones: En nuestra serie, los pacientes >50 años de edad se asociaron a características patológicas y evolutivas desfavorables al ser comparados con pacientes de menor edad. Sin embargo, creemos que el seguimiento no debiera limitarse exclusivamente a la edad, sino que debiera incluir el resultado de todas las variables pronósticas de malignidad en cáncer renal (AU)

Objectives: To evaluate clinical, pathological and evolutionary characteristics in different age groups with renal cancer. Materials and methods: A retrospective, descriptive and analytics analysis of 269 patients with renal cell cancer was made. Patients were divided in three groups according to age at the moment of diagnosis: <50 years old, between 50 y 65 years old and >65 years old. In each group clinical (age, sex, presence of clinical manifestations), pathological (tumor diameter, histological type, pathological stage (TNM2009), histological grade, presence of coagulative necrosis, microvascular invasion, presence of sarcomatoid elements, peripheral fat compromise, renal vein or inferior cava vein macroscopic vascular compromise, and nodes invasion) characteristics and presence of distance metastasis at diagnosis were evaluated. Univariated analysis of categorical variables was made by Chi square or Fischer test just as correspond; continuous variables were calculated by Student test. Main points, metastasis free and cancer-specific survival, were evaluated by Kaplan-Meier method and differences between groups by the Log-Rank test. Results: Of 269 patients studied, 40 (14.88%) were <50 years old group, 136 (50.55%) between 50 and 65 years old group and 93 (34.57%) >65 years old group. There are no significative differences when we evaluate clinical variables. Patients in <50 years old group had higher number of nephron-sparing surgery (p=0.04), lower histological grade (p=0.05), coagulative necrosis (p=0.002), peripheral fat invasion (p=0.02) and node invasion (p=0.05). Metastasis free survival at 5 years in this group was 95%; in 50-65 years old group and >65 years old group was 70% and 71%, respectively, with significant differences (Log-Rank test=0.004). Likewise, when we compared cancer-specific survival at 5 years between groups, we demonstrate that differences are significant in favor of patients younger than 50 years old (<50 years old 98%, 50-65 years old 79% and >65 years old 83%; Log-Rank test=0.02). Conclusions: In our series, age >50 years old is associated with unfavorable pathological and evolutionary characteristics to be compared with younger patients. However, we believe that the follow-up should not be limited only to the age but should include the results of all prognostic variables of malignancy in kidney cancer. (AU)

Obesity and kidney disease: hidden consequences of the epidemic / Obesidad y enfermedad renal: consecuencias ocultas de la epidemia

Abstract Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing Chronic Kidney Disease in the long-term. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.

Resumen La obesidad se ha convertido en una epidemia mundial, y se ha proyectado que su prevalencia se incrementará en un 40% en la próxima década. Esta creciente prevalencia supone implicaciones tanto para el riesgo de desarrollo de diabetes y enfermedades cardiovasculares como para el desarrollo de Enfermedad Renal Crónica. Un elevado índice de masa corporal es uno de los factores de riesgo más importantes para el desarrollo de Enfermedad Renal Crónica. En individuos afectados por la obesidad, tiene lugar una hiperfiltración compensatoria necesaria para alcanzar la alta demanda metabólica secundaria al aumento del peso corporal. El incremento de la presión intraglomerular puede generar daño renal y elevar el riesgo de desarrollar Enfermedad Renal Crónica a largo plazo. La incidencia de glomerulopatía asociada a obesidad se ha incrementado 10 veces en los últimos años. Así mismo se ha demostrado que la obesidad es un factor de riesgo para el desarrollo de nefrolitiasis y un número de neoplasias, incluyendo cáncer renal. Este año, el Día Mundial del Riñón promueve la educación a cerca de las consecuencias nocivas de la obesidad y su asociación con la enfermedad renal, abogando por un estilo de vida saludable y la implementación de políticas públicas de salud que promuevan medidas preventivas alcanzables.

Obesity and kidney disease: hidden consequences of the epidemic / Obesidade e doença renal: consequências ocultas da epidemia

Abstract Obesity has become a worldwide epidemic, and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for Chronic Kidney Disease. A high body mass index is one of the strongest risk factors for new-onset Chronic Kidney Disease. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing Chronic Kidney Disease in the long-term. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year the World Kidney Day promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.

Resumo A obesidade tornou-se uma epidemia mundial, e foi projetado que sua prevalência irá crescer em 40% na próxima década. Esta crescente prevalência tem implicações para com o risco de diabetes, doenças cardiovasculares e também para a doença renal crônica. Um índice de massa corporal elevado é um dos mais fortes fatores de risco para o desenvolvimento de doença renal crônica. Em indivíduos afetados pela obesidade ocorre uma hiperfiltração compensatória, para atender às elevadas exigências metabólicas do aumento de peso corporal. O aumento da pressão intraglomerular pode prejudicar os rins e aumentar o risco do desenvolvimento de doença renal crônica a longo prazo. A incidência de glomerulopatia relacionada à obesidade aumentou dez vezes nos últimos anos. A obesidade também mostrou ser um fator de risco para nefrolitíase, e para uma série de tumores malignos, incluindo câncer renal. Este ano, o Dia Mundial do Rim promove orientações sobre as consequências prejudiciais da obesidade e sua associação com a doença renal, defendendo estilos de vida saudáveis e políticas de saúde que tornam comportamentos preventivos uma opção acessível.

HPLC method development and validation for the estimation of Axitinib in rabbit plasma

ABSTRACT A rapid, sensitive, and accurate high performance liquid chromatography for the determination of Axitinib (AN) in rabbit plasma is developed using crizotinibe as an internal standard (IS). Axitinib is a tyrosine kinase inhibitor, used in the treatment of advanced kidney cancer, which works by slowing or stopping the growth of cancer cells. The chromatographic separation was performed on a Waters 2695, Kromosil (150 mm × 4.6 mm, 5 µm) column using a mobile phase containing buffer (pH 4.6) and acetonitrile in the ratio of 65:35 v/v with a flow rate of1 mL/min. The analyte and internal standard were extracted using liquid-liquid extraction with acetonitrile. The elution was detected by photo diode array detector at 320 nm.The total chromatographic runtime is 10.0 min with a retention time for Axitinib and IS of 5.685, and 3.606 min, respectively. The method was validated over a dynamic linear range of 0.002-0.2µg/mL for Axitinib with a correlation coefficient of r2 0.999.

Obesity and kidney disease: hidden consequences of the epidemic

Obesity has become a worldwide epidemic and its prevalence has been projected to grow by 40% in the next decade. This increasing prevalence has implications for the risk of diabetes, cardiovascular disease and also for chronic kidney disease (CKD). A high body mass index is one of the strongest risk factors for new-onset CKD. In individuals affected by obesity, a compensatory hyperfiltration occurs to meet the heightened metabolic demands of the increased body weight. The increase in intraglomerular pressure can damage the kidneys and raise the risk of developing CKD in the long-term. The incidence of obesity-related glomerulopathy has increased ten-fold in recent years. Obesity has also been shown to be a risk factor for nephrolithiasis, and for a number of malignancies including kidney cancer. This year, the World Kidney Day will promote education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option.

Clinical study of transperitoneal and retroperitoneal robot-assisted partial nephrectomy for renal hilar tumors / 中华泌尿外科杂志

Objective To investigate the clinical value and experience of transperitoneal and retroperitoneal robot-assisted partial nephrectomy for renal hi1 ar tumors.Methods We evaluated 48 patients who had partial nephrectomy for renal hilar tumor by robotic surgical syestem from January 2013 to March 2017.In those cases,35 were male and 13 were female,with an average age of 57.3 (range from 41 to 75 ),27 cases were ventral tumor and 21 cases were dorsal tumor.3 cases were totally confined to the renal parenchyma,the other 45 cases were partially confined to the renal parenchyma.18 cases were performed surgery by retroperitoneal route,the rest 30 cases were performed by peritoneal route.Results A total of 48 patients underwent successful robotic partial nephrectomy for renal hilar tumors.The mean warm ischemia time was 22 minutes (range from 16 to 33 minutes) and the mean estimated blood loss was 88 md (range from 50 to 350 ml).No bleeding-related complications were found.Histopathology confirmed 39 cases of ccRCC,7 cases of angioleiomyolipoma,2 cases of renal oncocytoma.There was one case in this review was positive surgical margin (2.1％) and found no sign of recurrence during the short term post-operation follow-up.All cases in this review are following up after surgery to date from 2 months to 4 years,no cases of tumor recurrence or metastasis were found.Conclusions The application of transperitoneal and retroperitoneal RAPN is the effective and safe way for renal hilar tumor resection,and it has a clear advantage of renal surgical incision stitching and tumor complete resection.The choice of surgical approaches depends on the size and location of tumor and the clinical experience of the surgeon.

Inhibition of Garcinia Acid to Kidney Cancer Cell Lines via Wnt3α/β-catenin Signal Pathway / 中国药师

Objective:To investigate the mechanism in growth inhibition of garcinia acid to kidney cancer cell lines ( RC-2 ) . Methods:RC-2 cells were cultured in vitro, and garcinia acid at various concentrations was co-cultured with RC-2 cells. The antipro-liferative activities were determined by CCK-8 assay, the percentage of apoptosis was determined by flow cytometry analysis, and the expression levels of Survivin and related proteins in Wnt3α/β-catenin signal pathway were measured using Western Blot analysis. Re-sults:After the treatment with garcinia acid for 24h and 48h, the proliferation of RC-2 cells was significantly suppressed by garcinia acid in a dose-dependent manner, and all garcinia acid groups had significantly higher apoptosis percentage of RC-2 cells than the con-trol group. In G0/G1 period, RC-2 cells reduced while increased in G2/M period, and in S period, the cells remained the same a-mount. The expression levels of Survivin, Wnt3α and β-catenin decreased in RC-2 cells after the treatment with garcinia acid. Con-clusion:Garcinia acid can inhibit the proliferation and promote the apoptosis of RC-2 cells, and the mechanism may be related with the inhibition of Wnt3α/β-catenin signal pathway and further decreasing the expression levels of Survivin.